Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

Structure Therapeutics (GPCR) said its GLP-1 pill helped patients lose over 16% of their weight, on average, in a 10-month drug trial, Bill Alpert of Barron’s writes. Weight loss continued the longer patients took the pill, with no plateau in sight, the company said. That’s more weight loss than was achieved in studies of the Wegovy pill that Novo Nordisk (NVO) began marketing in January, or a pill that Eli Lilly (LLY) is expected to launch soon. The performance of Structure’s pill may be good enough to make it an attractive takeover target for a larger pharmaceutical company looking to enter the drug industry’s fastest-growing category, the author notes.